- Health Canada has approved Exdensur (depemokimab) for severe eosinophilic asthma in patients aged 12+ and for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by standard treatments.
- Exdensur is the first and only long-acting biologic in Canada with twice-yearly dosing, offering one injection every six months for eligible patients.
- Approval was supported by the Phase III SWIFT and ANCHOR trials, where Exdensur significantly reduced asthma exacerbations, including those requiring hospitalization or emergency care, and improved nasal polyp size and nasal obstruction in CRSwNP patients.
- More than 4.7 million Canadians live with asthma, while hundreds of thousands are affected by CRSwNP. GSK says Exdensur’s IL-5-targeting mechanism and infrequent dosing could help improve long-term disease management and patient outcomes.
Takeaways:
Exdensur positions GSK as the first biologic in Canada with twice-yearly dosing for severe eosinophilic asthma, a major convenience advantage over existing IL‑4/5/13 and TSLP biologics that typically require every‑2‑to‑4‑week injections. [implied by query] This every‑6‑month schedule should improve adherence and long-term disease management.
Source: CA Newswire
